Intranasal NAD has been investigated experimentally, but the model must be named clearly. A 2026 study used cultured human olfactory stem cells and mice with experimentally induced loss of smell. It reported findings related to olfactory-cell differentiation and recovery in the animal model. Human-derived cells in a laboratory do not make the study a treatment trial in people. Intranasal NAD experiments in olfactory cells and mice

What the experiment can contribute

The work can help researchers formulate hypotheses about local biological effects and identify measurements for future studies. It cannot establish that a commercially available spray improves human energy, cognition or aging. Those claims involve different outcomes and may require different tissue exposure.

A mouse model of chemically induced olfactory injury also does not reproduce every cause of smell loss in people. Translating the result would require careful attention to the condition being treated, the formulation and clinically meaningful outcomes.

Delivery deserves independent evaluation

A nasal spray is a finished formulation and delivery system. Demonstrating activity in an experimental preparation does not establish the delivered amount, consistency, local tolerability or stability of another product. FDA's nasal-product guidance identifies these as substantive product-development questions. FDA nasal spray chemistry manufacturing and controls guidance

For AXON, the evidence summary should describe the study as preclinical and avoid letting a human-cell component blur that boundary. The primary source reviewed here does not establish efficacy or safety of a commercial NAD nasal spray in humans. Additional human evidence would need to be assessed on its own merits.

This article contains no instructions for preparing or using a spray. Persistent or sudden smell changes warrant appropriate clinical evaluation rather than reliance on an experimental product. Any broader therapeutic wording requires specialist review.